Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Venus Medtech HangZhou Inc (Venus MedTech) is a medical device company that develops and commercializes transcatheter heart valve products for structural heart diseases. The company's products include Venus-PowerX, Venus-Vitae, AR Valve, VenusA-Valve, VenusA-Plus, VenusA-Pro, VenusP-Valve, VenusA series, among others. Venus-PowerX, VenusA series, Venus-Vitae, AR Valveare are for the treatment of patients with aortic valve stenosis. Its pulmonary valve treats severe pulmonary regurgitation with or without RVOT stenosis, mitral valve for mitral and tricuspid valve diseases and Liwen RF and Echomplish Platform targets structural heart disease. Venus MedTech is headquartered in Hangzhou, Zhejiang, China.
Headquarters
China
Address
Room 311, 3/F, Block 2, No.88, Jiangling Road, Hangzhou, Zhejiang, 310051
Website
www.venusmedtech.com
No of Employees
560
Industry
Medical Equipment
Ticker Symbol & Exchange
2500 (HKG)
Revenue (2024)
$42.7M
-34.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
42.9%
(2024 vs 2023)
Market Cap*
$60.7M
Net Profit Margin (2024)
XYZ
12.4%
(2024 vs 2023)
* As of and is in US$
Venus Medtech Hangzhou Inc premium industry data and analytics
Products and Services
| Products |
|---|
| TAVR Products (Transcatheter Aortic Valve Replacement) |
| VenusA-Valve: Aortic Valve Disease |
| VenusA-Plus |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Venus Medtech Hangzhou Inc | Edwards Lifesciences Corp | Peijia Medical Ltd | MicroPort CardioFlow Medtech Corp | Colibri Heart Valve LLC |
|---|---|---|---|---|---|
| Headquarters | China | United States of America | China | China | United States of America |
| City | Hangzhou | Irvine | Suzhou | Shanghai | Louisville |
| State/Province | Zhejiang | California | Jiangsu | Shanghai | Colorado |
| No. of Employees | 560 | 16,000 | 1,022 | 1,415 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ting Yuk Anthony Wu | Chairman | Executive Board | 2019 | 72 |
| Meirong Liu | Vice President; Chief Operations Officer; Director | Executive Board | 2024 | 50 |
| Liqiao Ma | Director | Executive Board | 2023 | 41 |
| Lim Hou-Sen | Director; General Manager | Executive Board | 2023 | 52 |
| Bing Zhu | Chief Financial Officer | Senior Management | 2024 | 61 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer